I-Theranica, inkampani emiselweyo ye-digital therapeutical company ekuphuhliseni i-electroceuticals ephezulu ye-migraine kunye nezinye iimeko zentlungu, ibhengezwe namhlanje ukupapashwa kophando olutsha oluhlaziywa ngontanga oluhlalutya ukusebenza, ukhuseleko kunye nokugcinwa kwe-remote ye-neuromodulation yombane (REN) njengento yokuzimela, kunye neyeza zonyango, unyango lwe-migraine. Uphando lobungqina bokwenyani obupapashwe kwiFrontiers kwi-Pain Research Journal iqukumbela ukuba i-REN, elawulwa yi-Theranica's flagship product Nerivio®, yenza kakuhle kuzo zonke iiparameters ezintathu.
Iziphumo ezivela kuhlalutyo lwezonyango ezingaphezu kwe-23,000, eziqokelelwe kwithuba leenyanga ze-19, zibonise ukusebenza okubalulekileyo kwe-REN. Kwi-66.5% yonyango, i-REN isetyenziswe njengonyango oluzimeleyo. Malunga ne-80% yonyango, akukho mayeza amiselweyo asetyenzisiweyo. Ngaphandle kwezigulane ze-2,514 ezibandakanyiweyo kuhlalutyo olusebenzayo, i-32% yezigulane ze-episodic migraine kunye ne-21% yezigulane ezingapheliyo ze-migraine, zafumana inkululeko yeentlungu zeeyure ezimbini emva kokunyanga kuninzi lwezonyango zabo, kwaye ngaphezu kwe-65% bafumana intlungu eqhubekayo emva kweeyure ezimbini. . Kuhlalutyo lokhuseleko, kuphela i-59 yabathathi-nxaxheba be-12,368 (0.48%) babike naziphi na iziganeko ezibi ezinxulumene nesixhobo, uninzi lwazo zincinci (56) kungekho ngxelo yazo naziphi na iziganeko ezinzima.
I-Nerivio egqoke kwingalo ephezulu ekuqaleni kokuhlaselwa kwe-migraine, inciphisa intloko ye-migraine kunye neempawu ezihambelanayo ngokusebenzisa i-REN ukuqalisa indlela ye-analgesic engapheliyo, eyaziwa ngokuba yi-conditioned pain modulation (CPM). Isixhobo silawulwa nge-app ye-smartphone, ivumela izigulane ukuba zibeke ubuninzi bonyango lwabo kunye nokugcina idayari ye-migraine eyakhelweyo enokuthi yabelwane ngokulula noogqirha ukuze kuphuculwe ukulandelwa kwe-migraine kunye nokulawula.
I-Nerivio yinto emiselweyo, edityaniswe ngedijithali ukunxiba. Izifundo zeklinikhi zibonise ukuba i-Nerivio iyasebenza kwaye ikhuselekile kunyango lwe-episodic kunye ne-migraine engapheliyo kubantu abaneminyaka eyi-12 nangaphezulu.
INTO ONOKUYITHATHA KWELI NQAKU:
- Out of 2,514 patients included in the efficacy analysis, 32% of the episodic migraine patients and 21% of the chronic migraine patients, achieved pain freedom two hours post treatment in most of their treatments, and over 65% experienced sustained pain relief post two hours.
- Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced today the publication of a new peer-reviewed study analyzing the efficacy, safety and sustainability of remote electrical neuromodulation (REN) as a standalone, and medication adjunct, treatment of migraine.
- The device is controlled via a smartphone app, allowing patients to set the intensity of their treatment as well as maintain a built-in migraine diary that can easily be shared with physicians for improved migraine tracking and management.
